The first line of defense against respiratory
NorthLinks Bio is developing HEX17, a first-in-class intranasal antiviral designed to provide broad-spectrum protection against respiratory viruses at the point of entry before infection begins.
About Us
NorthLinksBio
Who We Are
A Company Founded on Pioneering Science
NorthLinks Bio is a clinical-stage biopharmaceutical company developing broad-spectrum protection against respiratory viruses. Our lead program, HEX17, has already demonstrated protection against influenza in a Phase 2 human challenge study.
Our Science
The Glycan-Targeted Platform
Our Glycan-Targeted Platform is based on engineered carbohydrate-binding modules (CBMs) designed to bind with high affinity to sialic acids present on the surface of respiratory epithelial cells. By masking host receptors, HEX17 prevents viral entry before infection begins.
This host-directed mechanism is designed to maintain activity regardless of viral evolution, offering the potential for broad protection against influenza, RSV, coronaviruses, rhinoviruses, and more.
Our Lead Program: HEX17
HEX17 is a self-administered intranasal spray engineered as a multivalent carbohydrate-binding module (mCBM) with substantially enhanced glycan-binding affinity. It is being developed as a broad-spectrum antiviral prophylactic for respiratory pathogens.
Our Program
Stay Informed
Follow our progress as we advance HEX17 toward further clinical development. For partnership inquiries, investor relations, or general questions, we'd like to hear from you.
